AXOVANT SCIENCES LTD. JEFFERIES HEALTHCARE CONFERENCE. Axovant Sciences Corporate Presentation -- June 2017 For Investor Use Only
|
|
- Hubert Benson
- 6 years ago
- Views:
Transcription
1 AXOVANT SCIENCES LTD. JEFFERIES HEALTHCARE CONFERENCE JUNE 7, 2017
2 FORWARD-LOOKING STATEMENTS Statements made in this presentation contain forward-looking statements, including statements regarding Axovant s expectations about timing of the results for the Phase 3 MINDSET study of intepirdine in patients with mild-to-moderate Alzheimer s disease on a stable background of donepezil therapy, the Phase 2b HEADWAY-DLB study of intepirdine in patients with DLB, the Phase 2 study of nelotanserin in patients with DLB or PDD suffering from visual hallucinations, the Phase 2 study of nelotanserin in patients with DLB suffering from RBD, the Phase 2 study of the effects of intepirdine on a background of cholinesterase inhibitor therapy on gait and balance in patients with Alzheimer s disease, DLB and PDD, the clinical studies of RVT-103 and RVT-104 and the licensed technology related to a combination of cholinesterase inhibitors and peripheral muscarinic receptor antagonists, and other elements of its clinical development and regulatory strategy. Forward-looking statements can be identified by the words believe, anticipate, continue, estimate, project, expect, plan, potential, intend, will, would, could, should or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates intepirdine, nelotanserin, RVT-103 and RVT-104; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant s views of the clinical study data. In addition, promising interim results or other preliminary analyses do not in any way ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim results. The drug candidates discussed are investigational and not approved and there can be no assurance that the clinical programs including the programs for intepirdine, nelotanserin, RVT-103, or RVT-104 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant s business in general, see the Risk Factors section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2017, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this presentation and speak only as of the date of this presentation. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law. 2
3 A X O VA N T C O M PA N Y O V E R V I E W AXOVANT: THE NEUROLOGY SOLUTIONS COMPANY Vision: Neurology Solutions Become the leading company focused on the treatment of dementia by broadly addressing multiple forms of the condition Lead Drug in Phase 3 for Alzheimer s Disease If the results of the MINDSET study are favorable, we plan to seek regulatory approval and commercialize intepirdine Global Leader in Lewy Body Dementia Phase 2b HEADWAY-DLB study of intepirdine ongoing Two Phase 2 studies of nelotanserin ongoing in patients with visual hallucinations and REM sleep behavior disorder Long-Range Plan Reinvest any potential profits from intepirdine and nelotanserin launches into developing disease-reversing therapies for Alzheimer s disease and Lewy body dementia, as well as other neurological diseases of significant unmet patient need 3
4 A X O VA N T S C I E N C E S, I N C. C O M PA N Y O V E R V I E W STRONG AND EXPERIENCED LEADERSHIP TEAM David Hung, M.D. Chief Executive Officer Marion McCourt President & Chief Operating Officer Lawrence Friedhoff, M.D., Ph.D. Chief Development Officer Greg Weinhoff, M.D. Chief Financial Officer Mark Altmeyer* Chief Commercial Officer Ilise Lombardo, M.D. Senior Vice President, Clinical Research * President of Axovant Sciences GmbH All trademarks are property of their respective owners. 4
5 A X O VA N T S C I E N C E S, I N C. C O M PA N Y O V E R V I E W RECENT KEY MANAGEMENT ADDITIONS Stephen Mohr General Counsel Eric Floyd, Ph.D. Senior Vice President, Regulatory Affairs Thomas Templeman, Ph.D. Senior Vice President, Pharmaceutical Operations and Quality Assurance Mark Wadley Senior Vice President, U.S. Business All trademarks are property of their respective owners. 5
6 A X O VA N T C O M PA N Y O V E R V I E W MARKET LEADING DEMENTIA PIPELINE Compound Indication Phase 1 Phase 2 Phase 3 Mild-to-moderate Alzheimer s disease Intepirdine (RVT-101) 5HT 6 receptor antagonist Dementia with Lewy bodies Gait and balance impairments in dementia Nelotanserin (RVT-102) 5HT 2A receptor inverse agonist REM sleep behavior disorder in Lewy body dementia Visual hallucinations in Lewy body dementia RVT-103 Glycopyrrolate + Donepezil RVT-104 Glycopyrrolate + High Dose Rivastigmine Alzheimer s disease Alzheimer s disease/ Lewy body dementia These are investigational drugs subject to FDA approval 6
7 A X O VA N T C O M PA N Y O V E R V I E W CATALYSTS IN 2017 Catalyst Expected Timing Intepirdine MINDSET Phase 3 Study Results Mild-to-moderate Alzheimer s disease Late September 2017 Intepirdine HEADWAY-DLB Study Results Dementia with Lewy bodies Q Intepirdine Phase 2 Study Results Gait and balance impairments in dementia 2017 Nelotanserin Phase 2 Study Full Results Visual hallucinations in Lewy body dementia 2H 2017 Nelotanserin Phase 2 Study Results REM sleep behavior disorder in Lewy body dementia 2H 2017 RVT-103 Proof-of-Concept Study Results 1H
8 INTEPIRDINE - I N TEPIRDINE: ALZHEIMER S DISEASE - I N TEPIRDINE: G AIT AND BALANCE I N AD, DLB, AND PDD
9 I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E INTEPIRDINE INCREASES ACETYLCHOLINE BY A DIFFERENT MECHANISM OF ACTION THAN DONEPEZIL Donepezil reduces acetylcholine breakdown in the synapse Intepirdine increases acetylcholine release into the synapse Intepirdine Acetylcholine level in the brain Donepezil Baseline Donepezil alone Intepirdine + donepezil Vehicle Intepirdine (1.0 mg/kg) Donepezil (0.3 mg/kg) Donepezil + intepirdine Donepezil (1.0 mg/kg) Donepezil + intepirdine Microdialysis studies in rats demonstrate increased acetylcholine levels over donepezil alone 1 1 Dawson, Intl. Review of Neurobiology, Vol. 96 9
10 I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E KEY HIGHLIGHTS OF INTEPIRDINE Validated Target (Acetylcholine) But New MOA (5HT6) Cholinesterase inhibitors improve cognition and function in dementia 5HT 6 receptor antagonists observed to promote the release of acetylcholine and other neurotransmitters 1 Strong Clinical Results of 5HT6 Inhibition in Phase 2 Lundbeck s idalopirdine with statistically significant effects on ADAS-cog in Phase 2 (n = 278) at 90mg/day Axovant s intepirdine with statistically significant effects on ADAS-cog and ADCS-ADL in Phase 2 at 35 mg/day Phase 3 MINDSET Study Design Mirrors Successful Phase 2 Study Phase 2 study: 684 patients, 15 and 35 mg/day, achieved statistical significance on endpoints ADAS-cog and ADCS-ADL at the 35 mg/day dose Phase 3 MINDSET study: 1,315 patients, 35 mg/day, primary endpoints are ADAS-cog and ADCS-ADL Strong Intellectual Property Position Composition of matter IP protection through 2029 (including anticipated PTE) Pending applications may extend patent life through Upton et al., Neurotherapeutics 2008, Vol. 5:3,
11 I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E ADJUNCTIVE THERAPY STUDY International, multi-center, double-blind, placebo-controlled trial in subjects with mild-tomoderate Alzheimer s disease (n = 684) Locations: U.S., Germany, Italy, Canada, Spain, Chile, Czech Republic, Argentina, Australia % completing WEEK 24 Primary Endpoints % completing WEEK 48 Intepirdine 35 mg Once daily on top of stable dose of donepezil (n = 236) 89% 210 subjects Intepirdine 35 mg Once daily on top of stable dose of donepezil (n = 194) 89% Intepirdine 35 mg Once daily on top of stable dose of donepezil (n = 172) 684 subjects * receiving stable dose of donepezil Intepirdine 15 mg Once daily on top of stable dose of donepezil (n = 221) 86% 191 subjects Intepirdine 15 mg Once daily on top of stable dose of donepezil (n = 170) 86% Intepirdine 15 mg Once daily on top of stable dose of donepezil (n = 147) * Two subjects did not receive a dose Randomization was stratified to achieve: MMSE 10-15: < 30% subjects MMSE 16-20: < 60% subjects MMSE 21-26: < 30% subjects Placebo Once daily on top of stable dose of donepezil (n = 225) 88% 198 subjects Placebo Once daily on top of stable dose of donepezil (n = 173) Double-Blind Treatment: 48 Weeks 87% Placebo Once daily on top of stable dose of donepezil (n = 151) 11
12 Change from Baseline ADAS-Cog I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E ADAS-COG BENEFIT OVER 48 WEEKS PRE-SPECIFIED ITT METHOD OF ANALYSIS* Treatment Effect 35 mg Intepirdine Visit Week 12 Difference vs. Donepezil Alone P Value Week Donepezil Alone 15 mg Intepirdine Plus 15 Donepezil mg RVT-101 Plus Donepezil 35 mg Intepirdine Plus 35 mg RVT-101 Plus Donepezil Donepezil Week 36 Week Weeks *Mixed Model Repeated Measure. Includes the following covariates: Baseline ADAS-cog Total Score, Baseline MMSE, Country Group, Visit, Time Since Diagnosis, Treatment, Baseline BMI, Baseline ADAS-cog Total Score by Visit, Baseline MMSE by Visit, Treatment by Visit 12
13 Change from Baseline in ADCS-ADL I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E ADCS-ADL BENEFIT OVER 48 WEEKS PRE-SPECIFIED ITT METHOD OF ANALYSIS* Treatment Effect 35 mg Intepirdine Visit Week 12 Difference vs. Donepezil Alone P Value Week Donepezil Alone 15 mg Intepirdine Plus 15 Donepezil mg RVT-101 Plus Donepezil 35 mg Intepirdine Plus 35 mg RVT-101 Plus Donepezil Donepezil Weeks Week 36 Week *Mixed Model Repeated Measure. Includes the following covariates: Baseline ADCS-ADL Total Score, Baseline MMSE, Country Group, Visit, Time Since Diagnosis, Treatment, Baseline BMI, Baseline ADCS-ADL Total Score by Visit, Baseline MMSE by Visit, Treatment by Visit 13
14 I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E PHASE 3 MINDSET TRIAL Designed to Replicate Success: Co-primary endpoints: ADAS-cog and ADCS-ADL Gold standard measures of cognition and function Two arms: intepirdine 35 mg and placebo Designed to reduce residual placebo response 600+ subjects per arm (>2x as many as prior trial) Added statistical power relative to prior trial Similar subject inclusion/exclusion criteria ClinicalTrials.gov Identifier: NCT Attention to Execution: MINDSET is powered to detect the treatment effects observed in the prior trial on ADAS-cog and ADCS-ADL Multiple enhancements implemented to improve MINDSET study quality Phase 3 MINDSET Design and Key Assessment Timeline 1,315 subjects receiving stable dose of donepezil Intepirdine 35 mg Once daily on top of stable dose of donepezil Placebo Once daily on top of stable dose of donepezil WEEK 24 Primary Endpoints Completing Subjects Eligible for Open-Label Extension Intepirdine 35 mg Once daily on top of any cholinesterase inhibitor and/or memantine WEEK 76 Safety and Tolerability Double-Blind Treatment: 24 Weeks Open-Label Extension: 52 Weeks 14
15 I N T E P I R D I N E : A L Z H E I M E R S D I S E A S E SIMILAR INCIDENCE OF ADVERSE EVENTS ACROSS TREATMENT AND PLACEBO ARMS Adverse Event Incidence of AEs occurring in 4% in any arm Week 48 Analysis: Safety Population Number (%) of Subjects Reporting Event Placebo + Donepezil (n = 225) Intepirdine 15 mg + Donepezil (n = 221) Intepirdine 35 mg + Donepezil (n = 236) Nasopharyngitis 17 (8) 19 (9) 18 (8) Urinary tract infection 16 (7) 11 (5) 13 (6) Diarrhea 9 (4) 12 (5) 11 (5) Fall 13 (6) 4 (2) 5 (2) Headache 6 (3) 8 (4) 7 (3) Bronchitis 3 (1) 4 (2) 9 (4) Nausea 8 (4) 4 (2) 4 (2) 15
16 I N T E P I R D I N E : G A I T A N D B A L A N C E I N A D, D L B, A N D P D D BOOSTING CHOLINERGIC FUNCTION HAS THE POTENTIAL TO REDUCE FALLS Prior Observations Incidence of Falls in Prior Studies of 5HT 6 Antagonists Intepirdine 866 Study (n = 684) Intepirdine + Donepezil: 2% Donepezil alone: 6% Idalopirdine LADDER Study (n = 278) Idalopirdine + Donepezil: 2% Donepezil alone: 6% In both trials of 5-HT6 receptor antagonists, the percentage of patients reporting falls was ~1/3 of the donepezil alone group 1 Henderson et al., Lancet Neurology (2016); Montero-Odasso et al., Journal of Alzheimer s Disease (2015); Li et al., European Neurology (2015); Mancini et al., BMC Neurology (2015). 16
17 I N T E P I R D I N E : G A I T A N D B A L A N C E I N A D, D L B, A N D P D D PHASE 2 GAIT AND BALANCE STUDY Description Population Double-blind, randomized, placebo-controlled, crossover study ClinicalTrials.gov Identifier: NCT ~40 subjects with diagnosis of Alzheimer s disease, DLB or PDD History of defined gait impairment On stable background therapy with acetylcholinesterase inhibitor Duration Two 14-day treatment periods 14-day washout period separates the two treatment periods Key Endpoints Changes in quantitative gait measurements (computerized assessment) Safety and tolerability ~40 subjects with diagnosis of AD, DLB, or PDD First Treatment Period Intepirdine 35 mg Placebo Second Treatment Period Intepirdine 35 mg Placebo 14 Days 14 Days Incidence of falls will also be captured in MINDSET and HEADWAY-DLB clinical studies 17
18 LEWY BODY DEMENTIA - LEWY BODY DEMENTIA BACKG ROUND - I N TEPIRDINE: DEMENTIA WITH LEWY BODIES
19 L E W Y B O D Y D E M E N T I A B A C KG R O U N D WHAT IS LEWY BODY DEMENTIA? Lewy Body Dementia (LBD) Approximately 1.4 million patients in the U.S. Dementia with Lewy Bodies (DLB) Parkinson s Disease Dementia (PDD) + Approximately 1.1 million patients in the U.S. Approximately 300,000 patients in the U.S. Distinctive Features of patients suffering from LBD include: Visual hallucinations, fluctuating cognition, attention and alertness, neuroleptic sensitivity, REM sleep behavior disorder (RBD), and movement disorder symptoms 19
20 L E W Y B O D Y D E M E N T I A B A C KG R O U N D CORE SYMPTOMS OF LEWY BODY DEMENTIA INTEPIRDINE COGNITIVE SYMPTOMS MOTOR SYMPTOMS NEUROPSYCHIATRIC SYMPTOMS REM SLEEP BEHAVIOR DISORDER 100% ~80% ~80% ~50-70% ~1.4 million LBD patients experience cognitive decline ~1.1 million LBD patients experience motor symptoms, including tremors and rigidity ~1.1 million LBD patients experience neuropsychiatric symptoms, including visual hallucinations ~700,000 to 1 million LBD patients experience REM sleep behavior disorder NELOTANSERIN Intepirdine and nelotanserin are investigational drugs subject to FDA approval 20
21 I N T E P I R D I N E : D E M E N T I A W I T H L E W Y B O D I E S POTENTIAL FIRST-IN-CLASS THERAPY FOR DLB Significant Unmet Need Cholinergic Deficits Cognition and Function Behavioral Disturbances No drugs approved in the U.S. or EU Aricept was approved in Japan for the treatment of DLB in 2014 A hallmark feature of DLB Cholinergic neurotransmission is MORE DYSFUNCTIONAL in DLB than Alzheimer s disease Increasing acetylcholine may improve cognition and function in DLB Intepirdine shown to promote the release of acetylcholine 5HT 2A activity is a potential driver of visual hallucinations * In addition to 5HT 6 activity, intepirdine is an antagonist of the 5HT 2A receptor HEADWAY-DLB includes both 35 mg and 70 mg doses of intepirdine to evaluate potential benefits of greater 5HT 2A receptor occupancy * Ballanger et al., Arch Neurol Vol. 67:4,
22 I N T E P I R D I N E : D E M E N T I A W I T H L E W Y B O D I E S PHASE 2B HEADWAY-DLB PROGRAM ADDRESSING COGNITION AND FUNCTION Description IND has Fast Track designation from FDA Double-blind, randomized, placebo-controlled study ClinicalTrials.gov identifier: NCT Population 240 subjects with diagnosis of DLB; MMSE score: (inclusive) Stable background therapy will be allowed Duration 24-week treatment period Active treatment extension following completion of treatment period Key Endpoints Change from baseline on CIBIC+ and a computerized cognitive battery Safety, tolerability, and change in behavioral symptoms 240 subjects with diagnosis of DLB Intepirdine 70 mg Intepirdine 35 mg Placebo WEEK 24 CIBIC+/CCB Primary Endpoints Double-Blind Treatment: 24 Weeks Completing Subjects Eligible for Active Treatment Extension Active Treatment Extension 22
23 NELOTANSERIN - VISUA L HALLUCINATIONS - MOTOR SYMPTOMS - REM SLEEP BEHAVIOR DISORDER
24 N E L O TA N S E R I N : R AT I O N A L E F O R L E W Y B O D Y D E M E N T I A D E V E L O P M E N T POTENTIAL BEST-IN-CLASS 5HT 2A INVERSE AGONIST Strong Binding Affinity Weak Binding Affinity Potential 1 st Generation 5HT 2A Inverse Agonist Potential Next Generation 5HT 2A Inverse Agonist Atypical Antipsychotics 1 Pimavanserin 2 Nelotanserin 3 5HT 2A Antagonism Ki binding affinity (nm) HT 2C Antagonism MIXED Ki binding affinity (nm) D 2 Antagonism Initial Target Market Parkinson s Disease Psychosis Lewy Body Dementia 1 Richtand et al., Neuropsychopharmacology Vol. 32:8, Nordstrom et al., Int J Neuropsychopharm Vol. 11:2, Investigational Drug Product, subject to FDA approval 24
25 N E L O TA N S E R I N O V E R V I E W NELOTANSERIN PHASE 2 PILOT STUDY IN LBD D L B & PDD SUBJEC TS E X P E R I EN CING F R EQ U EN T V I S UA L H A L LU C I N ATIONS Description Double-blind, randomized, placebo-controlled, crossover study ClinicalTrials.gov Identifier: NCT Population 20+ subjects with diagnosis of DLB or PDD; MMSE score 18 Frequent visual hallucinations (occurring on most days of the week) Duration Two 28-day treatment periods 28-day washout period separates the two treatment periods Key Endpoints Safety and tolerability, UPDRS II+III SAPS subscales including SAPS-PD, SAPS-PD-H, SAPS-H; Caregiver Diary First Treatment Period Second Treatment Period 20+ subjects with diagnosis of LBD (DLB or PDD) Nelotanserin 40 mg 80 mg Placebo 28 Days Nelotanserin 40 mg 80 mg Placebo 28 Days Completing Subjects Eligible for Open-Label Extension Open-label Extension Results to inform design of subsequent pivotal study 25
26 N E L O TA N S E R I N O V E R V I E W : M O T O R F U N C T I O N PRELIMINARY DATA SUGGEST NELOTANSERIN MAY IMPROVE MOTOR FUNCTION AS MEASURED BY UPDRS 11 subjects with either DLB or PDD completed treatment in both 4-week crossover periods Axovant plans to expand patient recruitment to confirm the treatment benefits observed in this study UPDRS Change from Baseline Relative to Placebo at Week 4 (N=11) Part II Part III Part II+III Delta relative to Placebo * ** * p-value = ** p-value = UPDRS Part II measures activities of daily living UPDRS Part III measures motor function 26
27 Number of Arousals N E L O TA N S E R I N : R E M S L E E P B E H AV I O R D I S O R D E R NELOTANSERIN PHASE 2 STUDY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN NUMBER OF AROUSALS FROM SLEEP Nelotanserin Phase 2 Objective Sleep Study n = 173 adult subjects with primary insomnia Nelotanserin showed statistically significant benefits on wake time after sleep onset, the primary endpoint Improvement -9 Number of Arousals Change from Screening (Pre-Specified Modified ITT Population) Night 1 and 2 Night 6 and 7-7 * = p < * * -3 * * Placebo 10 mg nelotanserin 40 mg nelotanserin Sources: Rosenberg et al., SLEEP 2008; McKeith et al., Neuropsychopharmacology
28 N E L O TA N S E R I N : R E M S L E E P B E H AV I O R D I S O R D E R NELOTANSERIN PHASE 2 STUDY IN LBD SUBJECTS EXPERIENCING REM SLEEP BEHAVIOR DISORDER (RBD) Description Population Duration Key Endpoints Double-blind, randomized, placebo-controlled study Designed as potentially pivotal study ClinicalTrials.gov Identifier: NCT ~60 subjects with diagnosis of LBD Frequent episodes of RBD (occurring on most days of the week) 28-day treatment period Sleep lab assessment at baseline and at end of the treatment period All completing subjects will be eligible for an open-label extension Change in frequency and severity of RBD episodes as measured in sleep lab Safety and tolerability, UPDRS II + III ~60 subjects with diagnosis of LBD experiencing RBD Nelotanserin 80 mg Placebo Double-Blind Treatment: 28 Days DAY 28 Primary Endpoints Completing Subjects Eligible for Open-Label Extension Open-Label Extension 28
29 RVT-103 AND RVT RATIONALE
30 R AT I O N A L E : R V T A N D R V T P R O G R A M S RATIONALE TO COMBINE CHOLINESTERASE INHIBITORS WITH PERIPHERAL MUSCARINIC RECEPTOR ANTAGONISTS Cholinesterase inhibitors (AChEIs) are dose-limited by gastrointestinal (GI) tolerability profile which limits patient adoption and compliance Muscarinic receptor antagonists may reduce the GI side effects of AChEIs and could support greater efficacy Glycopyrrolate and Trospium, unlike some muscarinic receptor antagonists, are believed to have minimal-to-no CNS penetration Glycopyrrolate or Trospium in combination with AChEIs may be superior to competitors by avoiding anticholinergic CNS effects 30
31 A X O VA N T S C I E N C E S T H E N E U R O L O G Y S O L U T I O N S C O M PA N Y AXOVANT IS UNIQUELY POSITIONED TO BE A LEADER IN NEUROLOGY SOLUTIONS Intepirdine could be the first NCE in AD since 2003 and has significant potential Intepirdine and nelotanserin have the potential to be the first two NCEs ever approved in U.S. and EU for DLB Building a portfolio of drugs to broadly address multiple neurological conditions 31
32 AXOVANT SCIENCES LTD. JEFFERIES HEALTHCARE CONFERENCE JUNE 7, 2017
Corporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationJ. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008
Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer s Disease J. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008 EPIX: GPCR Focused Drug Discovery
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationQuality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care
Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationINVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE. June 2013
INVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE June 2013 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationMay 9, Q Financial Results
May 9, 2017 Q1 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer Kimi
More informationPD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET
PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask Presented By: Alexander I. Tröster, PhD, ABPP University of North Carolina, Chapel Hill, NC Tuesday, March
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationSupportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Ginger S. Johnson, PhD Vice President Defined Health Todd Sherer, PhD Chief Executive
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID Concurrently, the Company Has Issued a Press Release Announcing the Presentation of Clinical Experience Data for NUPLAZID
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More information- The safety and efficacy of oral, once-daily VRAYLAR was established in a clinical trial program involving more than 2,700 patients
Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR TM (cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults - The safety and efficacy of
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationAmerican Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting. Walter E Kaufmann, MD CMO Nasdaq: AVXL March 2019
LONGITUDINAL 148-WEEK EXTENSION STUDY OF ANAVEX 2-73 FOR THE TREATMENT OF ALZHEIMER S DISEASE DEMONSTRATES MAINTAINED ACTIVITIES OF DAILY LIVING SCORE (ADCS-ADL) AND REDUCED COGNITIVE DECLINE (MMSE) FOR
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationSoliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018
Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationAEVI-001: SAGA Trial in mglur+ ADHD
AEVI-001: SAGA Trial in mglur+ ADHD Topline Results March 20, 2017 2017, Aevi Genomic Medicine Forward-Looking Statement This presentation includes certain estimates and other forward-looking statements
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationNUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months
Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson s Disease National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area:
More informationComprehensive Approach to DLB Management
Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationAppendix 5. Characteristics of included studies. Study title: NCT
Appendix 5 Characteristics of included studies Study title: NCT00818662 Study design: 'A Randomized, Double-Blind, Placebo-led, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationNew SEL-212 Phase 2 Data Presented at EULAR. June 15, 2018
New SEL-1 Phase Data Presented at EULAR June 15, 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ( the company
More informationPostpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S.
Sage Therapeutics Announces FDA Approval of ZULRESSO (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression March 19, 2019 Approval based on results from
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationThe most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.
Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationSCIENTIFIC DISCUSSION
London, 2 March 2006 Product name: Prometax Procedure number: EMEA/H/C/255/II/33 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationNorthera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension. September 2010
Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010 1 2004-2010 Chelsea Therapeutics, Inc. This presentation is being provided for
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationDeveloping treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need
Developing treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need Luke Beshar, senior vice president and chief financial officer BioNJ BioPartnering 2011
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationTonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
September 29, 2014 Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia Conference Call Today at 8:30 a.m. ET NEW YORK, Sept. 29, 2014
More information